NEWS COMMENTARY

Bayer agrees to 70% stake in personalized supplement company Care/of at $225 million valuation

Published:
September 07, 2020
Coverage:
Emerging Ecosystems in Agrifood and Health More...
Activities:
Acquisition More...
by Thomas Hayes
Very important

An official press release has yet to be released, but Bayer did confirm the deal with Forbes. This is the second acquisition of a personalized supplement company, the first being Nestlé's purchase of Persona in 2019. Persona and Care/of are very similar, with personalization aided solely by user-provided data (e.g., health goals). While we firmly challenge the credibility of this approach, it does seem to resonate with strategics given the ease of scalability, with Persona now in 60 countries since being acquired. Clients should recognize that this is merely the first step of an evolution, with personalization becoming more sophisticated over time. Stay tuned for our Lux Genius 2020 event to learn more about the personalization topic.

For the original news article, click here .


Further Reading

Telehealth company Hims looks to go public and expand remote mental health services

News Commentary | July 28, 2020

Hims is reported to be eyeing a deal that would allow it to go public. Should it do so, the company will be one of a few digital health IPOs to launch in the past year, but it is unique in that it will be approaching the provision of healthcare on a D2C model – not looking for a government subsidy ... To read more, click here.

Surprise over Google's dismantling of "consumer health" team misses the point

News Commentary | June 30, 2021

Google is reorganizing its health division, so far transferring almost a quarter of the staff to other divisions and funneling the remainder into three health groups – Care Studio, Health AI, and an unnamed group – to combine the Fitbit team with regulatory and equity staff. The lack of a "consumer ... To read more, click here.

Philip Morris acquires cardiopulmonary pharmaceutical company: The healthcare hero we need, not the one we deserve

Case Study | August 19, 2021

Philip Morris International (PMI), a wildly successful tobacco product manufacturer, has acquired inhaled therapeutics company OtiTopic. OtiTopic develops an inhaler‑based therapeutic for treating heart attacks quickly. Essentially, the company aerosolizes salicylic acid (aspirin) in order to get it... Not part of subscription